Diagnostic Test Accuracy Protocol
(13)β-D-glucan testing for the detection of invasive fungal infections in immunocompromised patients
Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
Published Online: 16 MAY 2012
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Schmidt RL, Schlaberg R, Hanson K. (13)β-D-glucan testing for the detection of invasive fungal infections in immunocompromised patients (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD009833. DOI: 10.1002/14651858.CD009833.
- Publication Status: New
- Published Online: 16 MAY 2012
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the diagnostic performance of BDG for diagnosis of invasive fungal infections (ECOG/MSG invasive or probable) in immunocompromized patients.
To compare the diagnostic performance of alternative tests (e.g. galactomannan) if head-to-head studies are available.
There are several possible sources of heterogeneity that could affect outcomes in this study. They include patient subgroups, reference test criteria (proven versus probable IFI), index test criteria (number of positive results required, sampling protocol, test cut-off values), the index test used (Fungitell versus Fungitec), and study design features (prospective versus retrospective). The EORTC/MSG criteria were developed in 2002 and subsequently revised in 2008 (Ascioglu 2002; De Pauw 2008). Thus, the change in criteria could be an additional source of heterogeneity. Finally, the time period between the evaluation of the index test (BDG) and the reference test (EORTC) could present another source of heterogeneity. Some studies use a cross sectional design in which the index test and reference test are evaluated at the same time. Others use a longitudinal design in which the reference test (EORTC) may be evaluated at some period after the index test.